Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Patients with metastatic cancer had better quality of life, clinical outcomes, and sense of well-being when they regularly ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Brice and Amanda Dieter of Jamestown had their figurative worlds upended in October 2023. It was at this time that the ...

Meeting the minimum requirement for vitamin B12, needed to make DNA, red blood cells and nerve tissue, may not actually be ...

A systematic risk assessment of more prevalent lymphoma entities, such as B cell and non-intestinal lymphomas, in coeliac disease has not been performed. Aims: In light of the increasing number of ...

Investment analysts at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report issued on Friday. The brokerage set a “sell” rating on the ...